M&A Deal Summary |
|
|---|---|
| Date | 2011-02-03 |
| Target | Eleme Medical |
| Sector | Medical Products |
| Buyer(s) | Cynosure |
| Sellers(s) | L Capital Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 5M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1991 |
| Sector | Medical Products |
| Employees | 857 |
| Revenue | 433M USD (2016) |
Cynosure, Inc. is a developer and marketer of aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure was founded in 1991 and is based in Westford, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 7 |
| Sector (Medical Products) | 3 of 6 |
| Type (Add-on Acquisition) | 1 of 4 |
| State (New Hampshire) | 1 of 1 |
| Country (United States) | 1 of 5 |
| Year (2011) | 1 of 2 |
| Size (of disclosed) | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-12-07 |
Suzhou Cynosure Medical Devices
Suzhou, China Cynosure China engages in the development, manufacture, and marketing of aesthetic treatment systems that are used by physicians and other practitioners to perform noninvasive procedures |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-10-05 |
The PinPointe FootLaser
United States The PinPointe FootLaser is the world's first FDA cleared light-based device for the treatment of Onychomycosis (toenail fungus), a condition that affects approximately 36 million people in the United States and an estimated 10 percent of the population worldwide. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2004 |
| PE ASSETS | 165M USD |
| Size | Small |
| Type | Sector Focused |
L Capital Partners is a specialist private equity firm focused on investing in companies operating within the healthcare, technology, and energy/environmental sectors, looking to bring 'groundbreaking products to market'. Within healthcare, L Capital looks to invest in biopharmaceutical and medical device businesses. Within technology, the Firm's emphasis is on security/defense and IT businesses. And within the energy/environmental sector, the L Capital's focus is investing in opportunities that 'improve the quality of life'. L Capital was formed in 2004 and has offices in New York City and Tel Aviv, Israel.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 7 |
| Sector (Medical Products) | 2 of 3 |
| Type (Add-on Acquisition) | 2 of 5 |
| State (New Hampshire) | 1 of 1 |
| Country (United States) | 4 of 7 |
| Year (2011) | 1 of 1 |
| Size (of disclosed) | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-04-09 |
Tengion
Winston-Salem, North Carolina, United States Tengion, Inc. is a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-11-01 |
OnPATH Technologies
Marlton, New Jersey, United States Provider of automated connectivity solutions, with a family of enterprise-class physical layer network connectivity switches purchased from Brocade. |
Sell | $40M |
